<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649465</url>
  </required_header>
  <id_info>
    <org_study_id>2015-033</org_study_id>
    <nct_id>NCT02649465</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD</brief_title>
  <official_title>Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanazawa University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kanazawa University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Objectives

        1. Which organ and how does SGLT2 inhibitor alter insulin sensitivity?

        2. How does SGLT2 inhibitor increase glucagon levels and hepatic glucose production?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2. Clinical hypothesis

        1. SGLT2 inhibitor ameliorates fatty liver and obesity.

        2. SGLT2 inhibitor stimulates sympathetic activity.

        3. SGLT2 inhibitor increases glucagon secretion.

        4. SGLT2 inhibitor enhances lipolysis and hepatic glucose production.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement in histologic features of NAFLD</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver enzymes</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body composition</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose level and glucose metabolism assessed with arginine tolerance test</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in organ-specific insulin sensitivity and glucagon response during a euglycemic hyperinsulinemic clamp study</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipid profile</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in renal function and electrolyte balances</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in oxidative stress</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cytokine (TNF-alpha, leptin, adiponectin) levels</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hepatokine (Selenoprotein P, LECT2) levels</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in organ-specific fat accumulation</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in oxidative and non-oxidative glucose disposal</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in respiratory quotients</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in energy expenditure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in autonomic nerve function.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in minerals and bone metabolism</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in endothelial functions</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in fatty acids profiles</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>19. Factors associated with the changes in autonomic nerve function, organ-specific fat accumulation, and glucagon response.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in gene expression profiles in the liver and blood cells</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in microRNAs and exosome contents</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenomic changes from baseline in genes of the liver and blood cells</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>SGLT2 inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N=20 SGLT2 inhibitor dosage (Tofogliflozin): a dose of 20mg once daily for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylurea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N=20 Sulfonylurea (Glimepiride): an initial dose of 0.5 mg once daily for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofogliflozin</intervention_name>
    <description>The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks</description>
    <arm_group_label>SGLT2 inhibitor</arm_group_label>
    <other_name>DEBERZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.</description>
    <arm_group_label>Sulfonylurea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The biopsy consistent with the diagnosis of NAFLD

          2. Type 2 diabetes, HbA1c &gt;=7.0%

        Exclusion Criteria:

          1. Hepatic virus infections (hepatitis C virus RNA-PCR-positive, hepatitis B and C,
             cytomegalovirus and Epstein-Barr virus), autoimmune hepatitis, primary biliary
             cirrhosis, sclerosing cholangitis, haemochromatosis, alpha 1-antitrypsin deficiency,
             Wilson's disease, history of parenteral nutrition and use of drugs known to induce
             steatosis (e.g. valproate, amiodarone and prednisone) or hepatic injury caused by
             substance abuse and/or the current or past consumption of more than 20 g of alcohol
             daily

          2. Hypersensitivity to or contraindication of glimepiride and tofogliflozin

          3. None- type 2 diabetes

          4. Poorly controlled diabetes (states of hyperglycemic hyperosmolar syndrome and diabetic
             ketoacidosis)

          5. Repeated episodes of unexplained hypoglycemia, as defined by a FPG &lt;60 mg/dl, with or
             without symptoms of hypoglycemia

          6. Concomitant infection or planned surgery

          7. Poorly controlled hypertension (systolic blood pressure &gt;160 mmHg, or diastolic blood
             pressure &gt;100 mmHg)

          8. Severe retinopathy

          9. Malignancy on an active therapeutic regimen or malignancy without complete remission
             or cure

         10. Severe health problems not suitable for the study

         11. Pregnant or lactating women

         12. Inability to participate in the study (psychiatric status or psychosocial status) as
             assessed by the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshinari Takamura, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Japan, Department of Disease Control and Homeostasis, Kanazawa university hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toshinari Takamura, MD,PhD</last_name>
    <phone>+81-76-265-2234</phone>
    <email>ttakamura@m-kanazawa.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yumie Takeshita, MD,PhD</last_name>
    <phone>+81-76-265-2234</phone>
    <email>takeshita@m-kanazawa.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Disease Control and Homeostasis, Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshinari Takamura, MD, PhD</last_name>
      <phone>+81-76-265-2234</phone>
      <email>ttakamura@m-kanazawa.jp</email>
    </contact>
    <investigator>
      <last_name>Yumie Takeshita, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanazawa University</investigator_affiliation>
    <investigator_full_name>Toshinari Takamura</investigator_full_name>
    <investigator_title>Department of Disease Control and Homeostasis</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

